The Institute for Biomathematics and Biometry conducts fundamental research in areas including Epidemiology, Analysis of Complex Experimental Data, Analysis of Environmental Chemicals, Machine Learning, Bacterial Communication Processes in the Rhizosphere, the Regulation Pathway of NF-κB and Coagulation Cascades.

Medigene Immunotherapies GmbH, part of MediGene AG, is a company headquartered in Planegg, Germany. The firm develops immunotherapy to treat cancer. It was founded in 2013 by Thomas Blankenstein and Dolores J. Schendel. Axel-Sven Malkomes is currently the CEO of the company. Medigene Immunotherapies GmbH was acquired by MediGene AG on January 27, 2014 for $13.05 million.\nThe company says this about itself: Based on more than 15 years of extensive research in the field of immunotherapy, Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH) was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100%subsidiary in January 2014. Medigene Immunotherapies pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC)vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.

Sotio is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers, and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells.

Life Science Institute strengthens and expands the healthcare business of the Mitsubishi Chemical Holdings (MCHC) Group. The company believes that the realization of a "society that continues to be healthy" is the solution that everyone can understand and the desired form of society. The LSII Group provides new value through comprehensive healthcare solutions to realize a "society that remains healthy" as a partner for patients suffering from various illnesses and all those who desire health.

Shanghai Suntech Biotechnology Co., Ltd., established on 2012-11-20, Business scope includes technology development in the field of biotechnology(human stem cells,Except for genetic diagnosis and treatment technology),technical consulting,technology transfer,Technical services and other related supporting services,Business Management Consulting Services,Health Information Consultation(except for medical diagnosis),laboratory instrument,laboratory consumables,laboratory reagent(Does not include medical devices,medicine,Hazardous Chemicals,Veterinary reagents)Wholesale.(Commodities that do not involve state trade management,Commodities involving quota license management,Commodities managed by special regulations,Handle in accordance with relevant national regulations). [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Asterias Biotherapeutics is a development-stage biotechnology company pioneering the field of regenerative medicine. It focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. It is also developing human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California.

Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies. The company's Imetelstat, an investigational first-in-class telomerase inhibitor, harnesses Nobel Prize-winning science in a treatment that may change the underlying course of these diseases. Geron was established in 1990 and is headquartered in Foster City, California.

Shanghai Hengsai Biotechnology Co., Ltd., established on 2018-11-26, Business scope includes general items:Engaged in technical services in the field of biotechnology,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Medical Research and Experimental Development;Chemical product sales(No licensed chemical products);Biochemical product technology research and development;R&D and application of cell technology;Sales of bio-based materials;Health Consulting Services(Does not include medical services);Import and export agency.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shenzhen Hornetcorn Biotechnology Co., Ltd. principally engages in the research and development of immune cell therapy technology and the provision of immune cell therapy technology to medical institutions. The company was founded on November 29, 2010 and is headquartered in Shenzhen, China.

JW CreaGene, Inc. engages in the manufacture of pharmaceutical products. The company was founded in 1998, and is headquartered in Seongnam-si, South Korea.

GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Cellid is a research and development bioventure company. The company is developing immunotherapeutic vaccines, CeliVax. The CeliVax is a personalized vaccine which uses patient's own cells.

DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.

Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain.

AIVITA Biomedical is is a medicine company, develops commercial and clinical-stage programs utilizing curative and regenerative medicines. AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its products and therapeutic pipeline.

Techno Network Shikoku connects universities and private companies to develop technologies and solve problems.

Beijing Heze Purui Biological Technology Co., Ltd., established on 2011-01-21, Business scope includes technology development,to promote,transfer,consult,Serve;sell cosmetics;Organize cultural and artistic exchange activities(without show);Undertake the exhibition.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)